Achim Sauer
-
- Immune Response and Inflammation 6
- Surgery top 10%
- Nephrology top 10%
- Pharmacology top 10%
- Cannabis and Cannabinoid Research 3
- Cholinesterase and Neurodegenerative Diseases 3
-
- Drug Transport and Resistance Mechanisms 6
-
- Computational Drug Discovery Methods 3
-
- Liver physiology and pathology 3
-
- Neuroscience and Neuropharmacology Research 3
-
- Retinal Diseases and Treatments 3
- Co-authors
- Frank HimmelsbachMatthias EckhardtPeter EickelmannThomas KleinRolf GremplerMichael MarkLeo ThomasThomas Härtung
- Journals
- Molecular Pharmaceutics (3 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Pharmaceutics (3 papers)
- Partner nations
- GermanyUnited StatesFinland
In The Last Decade
Achim Sauer
30 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Endocrinology, Diabetes and Metabolism 504
- Immunology 210
- Surgery 352
- Nephrology 44
- Pharmacology 102
Countries citing papers authored by Achim Sauer
This map shows the geographic impact of Achim Sauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Achim Sauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Achim Sauer more than expected).
Fields of papers citing papers by Achim Sauer
This network shows the impact of papers produced by Achim Sauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Achim Sauer. The network helps show where Achim Sauer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Achim Sauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 7 | |
| 3 | 2022 | 8 | |
| 4 | 2021 | 20 | |
| 5 | 2021 | 22 | |
| 6 | 2020 | 8 | |
| 7 | 2017 | 44 | |
| 8 | 2015 | 2 | |
| 9 | 2014 | 12 | |
| 10 | 2014 | 13 | |
| 11 | 2011 | 42 | |
| 12 | Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsbreakdown → | 2011 | 494 |
| 13 | 2011 | 13 | |
| 14 | 2002 | 16 | |
| 15 | Multi-Channel Marketing - Die Königsdisziplin im CRM? | 2002 | 6 |
| 16 | Multichannel Marketing - Fokus auf Kunden und Kanäle | 2002 | 3 |
| 17 | 1997 | 18 | |
| 18 | 1996 | 41 | |
| 19 | 1995 | 8 | |
| 20 | 1953 | 34 |
About Achim Sauer
Achim Sauer is a scholar working on Pharmacology, Hepatology, Pharmacology, Immunology and Ophthalmology, having authored 30 papers that have together received 1.1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (6 papers), Immune Response and Inflammation (6 papers), Computational Drug Discovery Methods (3 papers), Liver physiology and pathology (3 papers), Neuroscience and Neuropharmacology Research (3 papers), Cannabis and Cannabinoid Research (3 papers), Cholinesterase and Neurodegenerative Diseases (3 papers) and Retinal Diseases and Treatments (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (504 citations), Immunology (210 citations), Surgery (352 citations), Nephrology (44 citations) and Pharmacology (102 citations). Achim Sauer has collaborated with scholars based in Germany, United States and Finland. Frequent co-authors include Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann, Thomas Klein, Rolf Grempler, Michael Mark, Leo Thomas, Thomas Härtung, Albrecht Wendel and Remko A. Bakker. Their work appears in journals such as Molecular Pharmaceutics, Bioorganic & Medicinal Chemistry Letters, Pharmaceutics, Alzheimer s & Dementia and Drug Discovery Today.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.